亨迪药业
(301211)
| 流通市值：53.42亿 | | | 总市值：53.42亿 |
| 流通股本：2.88亿 | | | 总股本：2.88亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 234,768,347.93 | 114,446,404.92 | 445,864,331.31 | 333,993,687.09 |
| 营业收入 | 234,768,347.93 | 114,446,404.92 | 445,864,331.31 | 333,993,687.09 |
| 二、营业总成本 | 228,432,709.66 | 110,957,953.42 | 366,995,322.83 | 263,843,342.98 |
| 营业成本 | 183,347,719.02 | 89,066,678.92 | 317,273,551.06 | 233,021,231.04 |
| 税金及附加 | 2,848,941.96 | 1,187,937.57 | 4,247,887.93 | 2,863,447.78 |
| 销售费用 | 11,773,604.17 | 6,171,418.34 | 22,932,157.68 | 16,568,821.74 |
| 管理费用 | 21,221,244.83 | 10,436,125.93 | 39,291,513.02 | 29,226,852.36 |
| 研发费用 | 15,252,609.56 | 6,579,414.49 | 32,937,088.26 | 26,268,412.71 |
| 财务费用 | -6,011,409.88 | -2,483,621.83 | -49,686,875.12 | -44,105,422.65 |
| 其中:利息费用 | 98,603.11 | 47,717.84 | 312,272.59 | 183,046.45 |
| 其中:利息收入 | 6,191,921.59 | 2,634,150.89 | 46,876,919.83 | 43,297,639.2 |
| 加:公允价值变动收益 | 10,571,513.92 | 7,074,652.79 | 14,579,944.46 | 10,081,549.98 |
| 加:投资收益 | 4,282,814.18 | 513,097.22 | 4,448,988.52 | 1,178,016.32 |
| 资产处置收益 | 11,870.67 | - | - | - |
| 资产减值损失(新) | -2,029,344.38 | - | - | - |
| 信用减值损失(新) | -732,884.37 | -180,129.83 | -74,503.16 | -666,967.66 |
| 其他收益 | 1,996,637.25 | 1,620,203.03 | 3,058,569.66 | 2,215,080.91 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 20,436,245.54 | 12,516,274.71 | 100,882,007.96 | 82,958,023.66 |
| 加:营业外收入 | 106,800 | 2,654.87 | 6,000 | 84,432.93 |
| 减:营业外支出 | 21,358.63 | 18,661.81 | 468,998.18 | 461,899.76 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 20,521,686.91 | 12,500,267.77 | 100,419,009.78 | 82,580,556.83 |
| 减:所得税费用 | 1,974,604.33 | 2,174,182.42 | 8,871,630 | 7,919,010.55 |
| 六、净利润 | 18,547,082.58 | 10,326,085.35 | 91,547,379.78 | 74,661,546.28 |
| 持续经营净利润 | 18,547,082.58 | 10,326,085.35 | 91,547,379.78 | 74,661,546.28 |
| 归属于母公司股东的净利润 | 18,547,082.58 | 10,326,085.35 | 91,547,379.78 | 74,661,546.28 |
| (一)基本每股收益 | 0.06 | 0.04 | 0.32 | 0.26 |
| (二)稀释每股收益 | 0.06 | 0.04 | 0.32 | 0.26 |
| 八、其他综合收益 | -49,303.28 | - | -303,688.04 | - |
| 归属于母公司股东的其他综合收益 | -49,303.28 | - | -303,688.04 | - |
| 九、综合收益总额 | 18,497,779.3 | 10,326,085.35 | 91,243,691.74 | 74,661,546.28 |
| 归属于母公司股东的综合收益总额 | 18,497,779.3 | 10,326,085.35 | 91,243,691.74 | 74,661,546.28 |
| 公告日期 | 2025-08-01 | 2025-04-28 | 2025-04-24 | 2024-10-28 |
| 审计意见(境内) | 标准无保留意见 | | 标准无保留意见 | |